Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00178451
Status:
WITHDRAWN
Last Update Posted:
2015-12-18
First Post:
2005-09-12
Brief Title:
Stroke Prevention With Abciximab in Carotid Endarterectomy
Sponsor:
University of Rochester
Organization:
University of Rochester
Study Overview
Official Title:
Stroke Prevention With Abciximab in Carotid Endarterectomy
Status:
WITHDRAWN
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In the first portion of the study the goal will be to determine the safety of the drug Abciximab for use during and in the period after open carotid artery surgery In addition using specialized ultrasound equipment a probe that is placed on the outside of your skin of your head we will aim to measure the number of particles released around the time of surgery while being treated with Abciximab The second phase of the study will be determine if Abciximab can safely reduce the number of particles released into the bloodstream around the time of surgery in order to reduce the risk of stroke
Detailed Description:
Carotid endarterectomy is the most frequently performed vascular procedure in the United States In the last decade there has been a large increase in case volume following confirmation of the efficacy of endarterectomy for carotid artery atherosclerotic disease by the NASCET and ACAS trials Estimates for 1994 suggested that over 130000 patients underwent carotid endarterectomy in the United States
Despite the efficacy of endarterectomy over medical management for extra cranial cerebral vascular disease the risk of having an ipsilateral perioperative stroke after carotid endarterectomy remains at 2-7 There are two main types of operation-related stroke The intra-operative stroke is apparent upon recovery from anesthesia and is directly attributable to intra-operative ischemia or embolization The post-operative stroke occurs sometime after an uneventful recovery from surgery and is due to vessel occlusion or embolization off the thrombogenic endarterectomy surface Evidence suggests that platelets adhere to the exposed collagen of the endarterectomy surface within minutes of restoring flow The maximal rate of adherence appears to be one hour after clamp release Postoperative strokes are preceded by micro-particulate embolization which can be detected by transcranial Doppler ultrasound There is good correlation between TCD detection of 25 or more emboli in the middle cerebral artery distribution during any ten-minute period after surgery and an increased occurrence of transient ischemic attack and or stroke Another study found an embolic rate greater than 50 per hour predicted stroke in 50 of patients
Further study by TCD of the prevalence of post-operative micro particulate thromboembolic events after carotid endarterectomy found five percent of patients have sustained postoperative embolization The embolic rate is maximal in the first two hours postoperatively and if no evidence is found for embolization by the third post-operative hour then it is unlikely to occur thereafter Infusion of Dextran 40 has been shown to decrease the rate of embolization of micro particulate debris
Recent success in decreasing thrombotic events in both percutaneous coronary interventions and acute myocardial infarction with platelet glycoprotein IIBIIIA antagonists has stimulated interest in furthering the applications of these drugs A recent randomized clinical trial using Abciximab in acute ischemic stroke documented safety when administered up to twenty-four hours after stroke onset with a trend toward improvement in functional outcomes Abciximab has also been used in conjunction with heparin and aspirin in carotid artery percutaneous angioplasty and stenting and is thought to potentially reduce recurrent stenoses Unfortunately the use of platelet IIbIIIa inhibitors with open surgical procedures not been studied due to concerns of bleeding
Study Aims
Use of a platelet glycoprotein IIbIIIa antagonist holds great potential for diminishing or eliminating the micro particulate embolization seen with TCD and thus helping lower the combined operative morbidity and mortality to less than the five percent rate that is commonly accepted Our primary aim is to document the safety and ideal dosing of Abciximab for use in open vascular surgery namely Carotid Endarterectomy Our secondary aim is to evaluate the incidence of perioperative embolic events after carotid endarterectomy as monitored by transcranial Doppler with the perioperative administration of Abciximab
Despite the efficacy of endarterectomy over medical management for extra cranial cerebral vascular disease the risk of having an ipsilateral perioperative stroke after carotid endarterectomy remains at 2-7 There are two main types of operation-related stroke The intra-operative stroke is apparent upon recovery from anesthesia and is directly attributable to intra-operative ischemia or embolization The post-operative stroke occurs sometime after an uneventful recovery from surgery and is due to vessel occlusion or embolization off the thrombogenic endarterectomy surface Evidence suggests that platelets adhere to the exposed collagen of the endarterectomy surface within minutes of restoring flow The maximal rate of adherence appears to be one hour after clamp release Postoperative strokes are preceded by micro-particulate embolization which can be detected by transcranial Doppler ultrasound There is good correlation between TCD detection of 25 or more emboli in the middle cerebral artery distribution during any ten-minute period after surgery and an increased occurrence of transient ischemic attack and or stroke Another study found an embolic rate greater than 50 per hour predicted stroke in 50 of patients
Further study by TCD of the prevalence of post-operative micro particulate thromboembolic events after carotid endarterectomy found five percent of patients have sustained postoperative embolization The embolic rate is maximal in the first two hours postoperatively and if no evidence is found for embolization by the third post-operative hour then it is unlikely to occur thereafter Infusion of Dextran 40 has been shown to decrease the rate of embolization of micro particulate debris
Recent success in decreasing thrombotic events in both percutaneous coronary interventions and acute myocardial infarction with platelet glycoprotein IIBIIIA antagonists has stimulated interest in furthering the applications of these drugs A recent randomized clinical trial using Abciximab in acute ischemic stroke documented safety when administered up to twenty-four hours after stroke onset with a trend toward improvement in functional outcomes Abciximab has also been used in conjunction with heparin and aspirin in carotid artery percutaneous angioplasty and stenting and is thought to potentially reduce recurrent stenoses Unfortunately the use of platelet IIbIIIa inhibitors with open surgical procedures not been studied due to concerns of bleeding
Study Aims
Use of a platelet glycoprotein IIbIIIa antagonist holds great potential for diminishing or eliminating the micro particulate embolization seen with TCD and thus helping lower the combined operative morbidity and mortality to less than the five percent rate that is commonly accepted Our primary aim is to document the safety and ideal dosing of Abciximab for use in open vascular surgery namely Carotid Endarterectomy Our secondary aim is to evaluate the incidence of perioperative embolic events after carotid endarterectomy as monitored by transcranial Doppler with the perioperative administration of Abciximab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H4S-MC-1018 | None | None | None |